A Belfast diagnostics company has bagged £1.4 million in funding to develop its test for earlier and more accurate detection of ovarian cancer.
GenoME Diagnostics said it will use the investment to develop its lead product OvaMe, allowing the team to complete the testing phase, file for EU regulatory approval and expand its regulatory approach to the UK and North America. It will also allow the GenoME team to extend their novel technology to additional cancer types and enable them to consider further research into additional disease areas.
The firm also said it intends to expand headcount in the future.
